Gonadorelin: The Peptide Preserving Fertility and Testicular Function in TRT Protocols (2026)

If you've researched testosterone replacement therapy (TRT), you've almost certainly encountered gonadorelin. As HCG (human chorionic gonadotropin) has become increasingly difficult to obtain through compounding pharmacies, gonadorelin has stepped in as the primary clinical alternative for men who want to preserve testicular function and fertility while on exogenous testosterone. This guide covers the science, dosing, and honest clinical picture.

What Is Gonadorelin?

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide (10 amino acid) hormone naturally produced and released by the hypothalamus. Its amino acid sequence is identical to endogenous GnRH.

In the United States, gonadorelin was previously marketed under brand names Factrel (diagnostic use) and LutrePulse (pulsatile subcutaneous delivery via infusion pump). Both products have been discontinued, though the compound remains available through 503A compounding pharmacies with a valid prescription.

Gonadorelin is not the same as GnRH agonist analogs like leuprolide (Lupron) or nafarelin. Those compounds have modified sequences that make them long-acting and paradoxically suppressive, used in oncology and endometriosis treatment. Gonadorelin is the native sequence, designed to mimic the body's own pulsatile signaling.

How Gonadorelin Works: The HPG Axis

To understand why gonadorelin matters in TRT, you need to understand the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal feedback loop governing testosterone and sperm production.

Under normal physiology:

1. The hypothalamus releases GnRH in pulses approximately every 90 minutes.
2. Each GnRH pulse signals the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
3. LH stimulates Leydig cells in the testes to produce testosterone. FSH stimulates Sertoli cells to support spermatogenesis.

When a man begins exogenous testosterone therapy, elevated testosterone levels halt GnRH pulsing. Without GnRH, LH and FSH drop to near zero. Without LH, Leydig cells stop producing testosterone and the testes shrink (testicular atrophy). Without FSH, sperm production declines sharply — often to azoospermia within months.

Gonadorelin works by replacing the missing GnRH signal, prompting the pituitary to continue releasing LH and FSH even in the presence of exogenous testosterone.

The Critical Pulsatile Requirement

GnRH must be delivered in pulses to be effective. Continuous exposure to GnRH paradoxically downregulates GnRH receptors — the same mechanism exploited by GnRH agonists to suppress testosterone in prostate cancer treatment.

Gonadorelin has a distribution half-life of 2 to 10 minutes and terminal half-life of 10 to 40 minutes. This brevity is a feature: each subcutaneous injection creates a brief pulse that stimulates LH/FSH release and clears rapidly, preventing receptor downregulation.

Gonadorelin in TRT: Clinical Applications

1. Preventing Testicular Atrophy

Testicular shrinkage is one of the most common complaints among men on TRT. LH stimulation is the primary driver of testicular volume, so supplementing with gonadorelin helps maintain Leydig cell activity and intratesticular testosterone, preserving testicular size and scrotal fullness.

2. Preserving Fertility

For men of reproductive age who want to maintain fertility while on TRT, gonadorelin aims to keep FSH signaling active enough to sustain spermatogenesis. This is a more demanding application, and twice-daily subcutaneous injections are an imperfect approximation of the natural 90-minute GnRH cycle. Men with serious fertility goals may be better served by HCG (where available) or by temporarily discontinuing TRT.

Gonadorelin vs. HCG: A Practical Comparison

HCG was long the gold standard TRT add-on for preserving testicular function. HCG mimics LH directly — binding LH receptors on Leydig cells without needing to go through the pituitary. It is generally more effective than gonadorelin for both testicular volume and fertility.

So why has gonadorelin largely replaced HCG in many TRT clinics? In 2020, the FDA reclassified HCG as a biologic, dramatically restricting compounding pharmacy access. Only a small number of 503B outsourcing facilities can legally manufacture compounded HCG, and supply has become inconsistent and costly.

Gonadorelin remains available through 503A compounding pharmacies with a prescription and is synthetically produced, making it easier to compound and more accessible nationwide.

A key advantage of gonadorelin over HCG: because it works upstream through the pituitary rather than directly on testicular tissue, it causes less aromatase activation, resulting in lower estradiol elevation — a significant practical benefit for men sensitive to estrogen side effects.

Dosing Protocols

Gonadorelin for TRT adjunct use is typically compounded as a 1 to 5 mg/mL solution for subcutaneous injection:

• Standard TRT adjunct dose: 100 to 200 mcg subcutaneously, twice daily (approximately 12 hours apart)
• Injection site: Abdomen, rotating sites to minimize localized irritation
• Duration: Most protocols use gonadorelin continuously while on TRT

For diagnostic pituitary testing, the standard protocol is 100 mcg IV or subcutaneous with LH/FSH measurements at 15, 30, 45, 60, and 90 minutes post-injection.

For hypothalamic hypogonadism and fertility induction, gonadorelin is ideally delivered via pulsatile infusion pump at 5 to 20 mcg every 90 minutes — closely approximating natural hypothalamic pulsatility and far more effective for fertility, but significantly more complex to manage.

Reconstitution and Storage

• Use bacteriostatic water (not sterile water) for multi-use vials
• Store reconstituted solution refrigerated at 2 to 8 degrees Celsius
• Use within 28 to 30 days of reconstitution per pharmacy guidance
• Allow to reach room temperature before injection to reduce discomfort

Side Effects and Safety

Gonadorelin has a well-established safety record. At TRT-adjunct doses, the side effect profile is mild:

• Injection site reactions: Mild redness, swelling, or irritation — the most commonly reported effect
• Headache: Occasional, typically mild and transient
• Flushing: Brief warmth shortly after injection
• Nausea: Rare, at higher doses
• Dizziness: Uncommon

Gonadorelin does not cause insulin resistance, does not elevate IGF-1, and does not suppress the HPG axis — making it fundamentally safer than anabolic steroids or GnRH agonist drugs.

Legal and Regulatory Status

• FDA status: Previously approved (Factrel, LutrePulse) — both discontinued, but compound is recognized
• 503A compounding: Available with a valid prescription
• Prescription required: Yes — cannot be obtained OTC or as a research chemical for human use
• WADA: Prohibited in competitive sport

The regulatory picture for gonadorelin is notably more stable than for many compounded peptides. It has not appeared on the FDA's Category 2 list of substances that may not be compounded.

How to Access Gonadorelin Legitimately

1. Work with a TRT-experienced provider — men's health clinics, urologists, or endocrinologists specializing in hormone therapy
2. Get baseline labs — total testosterone, free testosterone, LH, FSH, estradiol, prolactin, and SHBG before starting
3. Verify pharmacy credentials — PCAB-accredited or state board-licensed pharmacies with a COA for each batch
4. Set realistic expectations — gonadorelin as a TRT adjunct is off-label use; understand the evidence and alternatives

The Bottom Line

Gonadorelin is a legitimate, well-understood peptide with a clear mechanism, decades of clinical history, and a reasonable safety profile. For men on TRT who want to reduce testicular atrophy or keep a fertility option open, it fills a real clinical gap — particularly as HCG has become harder to access.

Its limitations are real: the short half-life requires twice-daily injections, an imperfect approximation of natural pulsatile GnRH signaling. For men with serious near-term fertility goals, gonadorelin alone may not be sufficient and a reproductive endocrinologist consultation is warranted.

For the majority of TRT patients seeking to preserve testicular function and maintain HPG axis biology, gonadorelin is a practical, accessible, and clinically defensible option that will likely remain a cornerstone of TRT protocols for years to come.

This article is for educational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide or hormone therapy.